In the latest market developments, Sealsq Corp (LAES) emerged as a prominent name in the financial sector with a significant surge in its indicative borrow rate. The rate for LAES experienced a substantial jump, increasing by 8.74 percentage points to reach 120.67%. This marked it as the most notable increase among the stocks in the liquid options category.
Other companies also witnessed notable changes, albeit less pronounced than Sealsq Corp. Weight Watchers (WW) followed with an increase of 7.95 percentage points, bringing its borrow rate up to 22.88%. FingerMotion (FNGR) saw its rate rise by 3.04 percentage points to 17.41%, while ProShares UltraShort Lehman 20 Plus Year Treasury (TBT) increased by 1.29 percentage points to a total of 9.11%.
Crispr Therapeutics (CRSP, Financial) and ETF OPPORTUNITIES TRUSTT-REX 2X INVERSE (TSLZ) also experienced increments, with CRSP climbing by 1.25 points to 22.63%, and TSLZ increasing by 0.83 points, reaching 31.56%. The list of significant changes continued with Kingsoft Cloud Holdings (KC), which saw a rise of 0.68 points to 22.90%, and DEFIANCE DAILY TARGET 1.5X SHORT MSTR ETF (SMST), which increased by 0.61 points to 39.52%.
Lesser yet noteworthy increases were observed in Knight Transportation (KNX), which edged up by 0.36 points to 0.61%, and Designer Brands (DBI), whose rate rose by 0.34 points to 0.95%.
This data highlights the dynamic shifts in borrowing rates across various liquid option stocks, underscoring Sealsq Corp's considerable rate increase as a standout in the current financial landscape.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 23 analysts, the average target price for CRISPR Therapeutics AG (CRSP, Financial) is $82.00 with a high estimate of $268.00 and a low estimate of $32.00. The average target implies an upside of 108.65% from the current price of $39.30. More detailed estimate data can be found on the CRISPR Therapeutics AG (CRSP) Forecast page.
Based on the consensus recommendation from 28 brokerage firms, CRISPR Therapeutics AG's (CRSP, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CRISPR Therapeutics AG (CRSP, Financial) in one year is $25.46, suggesting a downside of 35.22% from the current price of $39.3. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CRISPR Therapeutics AG (CRSP) Summary page.
